Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
Top Cited Papers
Open Access
- 16 March 2006
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 20 (6) , 1103-1108
- https://doi.org/10.1038/sj.leu.2404149
Abstract
Mutations in exon 12 of the nucleophosmin (NPM1) gene occur in about 60% of adult AML with normal karyotype. By exploiting a specific feature of NPM1 mutants, that is insertion at residue 956 or deletion/insertion at residue 960, we developed highly sensitive, real-time quantitative (RQ) polymerase chain reaction (PCR) assays, either in DNA or RNA, that are specific for various NPM1 mutations. In all 13 AML patients carrying NPM1 mutations at diagnosis, cDNA RQ-PCR showed >30 000 copies of NPM1-mutated transcript. A small or no decrease in copies was observed in three patients showing partial or no response to induction therapy. The number of NPM1-mutated copies was markedly reduced in 10 patients achieving complete hematological remission (five cases: NPM1 copies closely correlated with clinical status and predicted impending hematological relapse in two. Thus, reliable, sensitive RQ-PCR assays for NPM1 mutations can now monitor and quantify MRD in AML patients with normal karyotype and NPM1 gene mutations.Keywords
This publication has 18 references indexed in Scilit:
- Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutationsBlood, 2005
- Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotypeBlood, 2005
- Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotypeBlood, 2005
- Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemiaLeukemia, 2004
- Minimal residual disease monitoring by flow cytometryBest Practice & Research Clinical Haematology, 2003
- Prognostic Value of Minimal Residual Disease Quantification by Real-Time Reverse Transcriptase Polymerase Chain Reaction in Patients With Core Binding Factor LeukemiasJournal of Clinical Oncology, 2003
- Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspectsLeukemia, 2003
- Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patientsLeukemia, 2002
- Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcriptsLeukemia, 2002
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998